Core Insights - UniQure (NASDAQ:QURE) is recognized as a leading gene therapy stock by hedge funds, with Wolfe Research initiating coverage with a Peer Perform rating, pending further clarity on its lead program AMT-130 [1] - H.C. Wainwright has reiterated a Buy rating for UniQure, setting a price target of $70.00, citing the strengthening of its gene therapy platform and promising data related to Fabry disease [2][3] Company Overview - UniQure focuses on discovering, developing, and commercializing innovative gene therapies aimed at treating conditions such as Huntington's disease, glybera, hemophilia, and cardiovascular issues [4] Investment Considerations - The emerging safety profile and manageable liver enzyme elevations are seen as constructive for future dosing, contributing to the long-term value of UniQure that is not yet reflected in its current share price [3] - Despite the potential of UniQure as an investment, some analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [5]

Financial Performance - uniQure N.V. anticipates a quarterly loss of $0.93 per share with projected revenue of approximately $4.7 million [1][6] - The company has a negative price-to-earnings (P/E) ratio of -4.26, indicating a lack of profitability [3][6] - The price-to-sales ratio is 66.94, suggesting that investors are paying a high premium for each dollar of sales [3][6] - The enterprise value to sales ratio stands at 33.23, further reflecting financial challenges [3] Legal Challenges - uniQure is currently involved in a class action lawsuit for alleged violations of securities laws, which may impact its financial performance [2][6] - The lawsuit claims that the company made false and misleading statements regarding its Pivotal Study design and its comparison to the ENROLL-HD data set, contributing to delays in securing full FDA approval for its Biologics License Application (BLA) [2] - Additional class action lawsuits have been announced by the Schall Law Firm and Rosen Law Firm, targeting investors who purchased QURE shares between September 24, 2025, and October 31, 2025 [5] Financial Metrics - Despite financial struggles, uniQure maintains a relatively low debt-to-equity ratio of 0.29, indicating conservative debt usage [4] - The company's current ratio of 7.12 suggests strong liquidity, allowing it to cover short-term liabilities [4] - However, the negative enterprise value to operating cash flow ratio of -3.42 and an earnings yield of -23.48% highlight ongoing financial challenges [4]

Group 1 - The article discusses the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The Haggerston BioHealth group provides insights on catalysts, buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-specific analyses for major pharmaceutical companies [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file with the court by April 13, 2026, acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including FDA approval status and the potential delay in its Biologics License Application (BLA) timeline [5]. - The defendants allegedly downplayed the likelihood of needing additional studies, which led to misleading statements about uniQure's business and prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 13, 2026, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the design of its Pivotal Study for a drug candidate targeting Huntington's Disease, which was not fully approved by the FDA [4] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [4] - The lawsuit asserts that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [4]

SAN DIEGO, Feb. 26, 2026 /PRNewswire/ --Â Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure N.V. is based in Amsterdam and focuses on developing and commercializing gene therapies for severe diseases, particularly Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250%, from $13.66 to $47.50 per share, following positive statements [3]. - On November 3, 2025, it was revealed that the FDA agreement on study design was not finalized, causing a stock price drop of over 49%, from $67.69 to $34.29 per share [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Case Allegations - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the approval status of its Pivotal Study by the FDA [5] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [5] - The lawsuit asserts that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly making materially false and misleading statements regarding its business and operations during the specified class period from September 24, 2025, to October 31, 2025 [2][3] Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased uniQure ordinary shares during the class period [2] - Investors have until April 13, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2] Group 2: Allegations - The complaint alleges that uniQure's management made materially false statements and failed to disclose adverse facts about the company's business [3] - Specific allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline [3] - As a result, the statements made by the defendants regarding the company's business and prospects lacked a reasonable basis [3] Group 3: Next Steps for Investors - Investors who purchased uniQure shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4] - The law firm offers a no-cost consultation for affected investors [4]

Core Viewpoint - The article discusses a class action lawsuit against uniQure N.V. related to alleged securities fraud, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased uniQure securities between September 24, 2025, and October 31, 2025 [1]. - Allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies [1]. Company Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from Phase I/II studies of AMT-130 would be adequate for BLA submission, leading to uncertainty regarding the BLA submission timeline [1]. - Following this disclosure, uniQure's share price fell by $33.40, approximately 49.33%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1].